Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

Outlook Therapeutics (Nasdaq: OTLK) announced that CEO Bob Jahr will participate in a live fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:00 AM ET.

Management is also available for one-on-one in-person meetings with qualified, registered investors at the conference. A live webcast will be available on the company Investors > Events page and the replay will be archived for 90 days after the event.

News Market Reaction

-4.26%

30 alerts

-4.26% News Effect

+2.7% Peak Tracked

-15.4% Trough Tracked

-$4M Valuation Impact

$80M Market Cap

1.0x Rel. Volume

On the day this news was published, OTLK declined 4.26%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.7% during that session. Argus tracked a trough of -15.4% from its starting point during tracking. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $80M at that time.

Data tracked by StockTitan Argus on the day of publication.

Live webcast fireside chat on Tuesday, December 2nd at 10:00 AM ET

ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the Piper Sandler 37^th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:00 AM ET.

In addition to the fireside chat, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.

A live webcast of the fireside chat will be accessible on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com

FAQ

When will Outlook Therapeutics (OTLK) present at the Piper Sandler 2025 conference?

CEO Bob Jahr will speak in a fireside chat on December 2, 2025 at 10:00 AM ET.

How can investors watch the Outlook Therapeutics (OTLK) fireside chat webcast?

Watch the live webcast on the company's Investors > Events page at outlooktherapeutics.com.

Will Outlook Therapeutics (OTLK) offer meetings with management at the conference?

Yes; management is available for one-on-one in-person meetings with qualified, registered investors at the conference.

How long will the Outlook Therapeutics (OTLK) webcast replay be available?

The webcast replay will be archived and available for 90 days following the event.

What topics will Outlook Therapeutics (OTLK) cover in the fireside chat on December 2, 2025?

The company will discuss recent developments and corporate outlook; the announcement specifies a CEO fireside chat but does not list detailed topics.